Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

24 March 2015

US pharma major Bristol-Myers Squibb (NYSE: BMY) has agreed to acquire from Danish diabetes care giant Novo Nordisk (NOV: N) an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.

Terms of the agreement were not disclosed, but news of the deal sent Novo Nordisk’s shares up 1.7% to 344.90 Danish kroner by mid afternoon today, while B-MS dipped 1.2% to $66.75. Novo Nordisk is divesting the assets as it focuses further on diabetes care.

The agreement supports Bristol-Myers Squibb’s long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK